The EFEMP1 coding region extends over a genomic interval of 56485 bp and comprises 10 exons. EFEMP1 proximal promoter lacks TATA or CAAT regulatory boxes and is rich with CG residues. EFEMP1 expression is repressed by promoter methylation in several cancer types and cancer cell lines. Primers used to detect EFEMP1 promoter methylation are show in figures 2 and 3.
DNA/RNA

Transcription
The EFEMP1 coding region extends over a genomic interval of 56485 bp and comprises 10 exons. EFEMP1 proximal promoter lacks TATA or CAAT regulatory boxes and is rich with CG residues. EFEMP1 expression is repressed by promoter methylation in several cancer types and cancer cell lines. Primers used to detect EFEMP1 promoter methylation are show in figures 2 and 3.
Protein
Note
The two transcription variants encode the same EFEMP1 protein of 493-amino acids with a molecular mass of ~ 55 kDa. Consecutive exons from 4 to 9 encode tandem arrays of epidermal growthfactor (EGF)-like domains. There is no EFEMP1 ortholog in non-mammalian species, indicating its recent evolution in higher vertebrates with intragenic exon duplications. There are 92-94% similarity at protein level among EFEMP1 of human, rat and mouse.
Description
EFEMP1 belongs to seven-member family of secreted glycoproteins characterized by a N-terminal signal peptide, a tandem repeat of EGF-like domains and a unique C-terminal fibulin-type module.
Expression
EFEMP1 is broadly expressed throughout the body during development and in adult tissues. It is highly expressed by epithelial and endothelial cells.
Localisation
Extracellular matrix.
Function
EFEMP1 is one member of fibulins that serve to modulate cellular behavior and functions by connecting and integrating multiple partner molecules in extracellular compartment. EFEMP1 is likely to contribute the integrity of basement membrane zones and anchor other extracellular matrix structures such as elastic fibers to basement membranes. Studies based on Efemp1 knock-out mouse implicate EFEMP1 function in withholding tissue integrity by stimulating the expression of Timp1 and Timp3 and inhibiting the expression and activities of matrix metalloproteinase Mmp2, and Mmp9 (Rahn et al., 2009 ). EFEMP1 interacts with TIMP3 (Klenotic et al., 2004) and hepatitis B virus X antigen (Sun et al., 1998) . EFEMP1 suppresses endothelial cell spouting and antagonizes angiogenesis in vivo (Albig et al., 2006) . EFEMP1 interacts with EGFR . However, opposing effects from EFEMP1 on EGFR-AKT signaling activity were reported in different cancer cells, to promote or suppress (Hu et al., 2011; Hwang et al., 2010; Kim et al., 2012) cancer cell migration/invasion and/or in vivo tumor growth. A Delta-Serrate-Lag motif in EGF-like module with insertion has been revealed to be responsible for EFEMP1-mediated activation of Notch signaling in glioma cells (Hu et al., 2012) .
Homology
EFEMP1 shares homology with the other members of fibulin family on (EGF)-like domains and fibulintype module.
Mutations
Germinal
A single mutation of EFEMP1 gene at R345W was identified in patients with Malattia Leventinese (ML) and Doyne honeycombe retinal dystrophy (DHRD) (Stone et al., 1999) . Severe atropy of the retina was observed in patients with this mutation, including absence of photoreceptor and RPE cells, and large fibrous scars in the macular region. This mutation was reported to cause protein misfolding, so that it is secreted inefficiently and retained within cells (Marmorstein et al., 2002) .
Comparison of pathological features of Efemp1 knockout and R345W knock-in mice suggests R345W mutation in causing macular degeneration is not due to loss of EFEMP1, so it is likely that the mutation has an added detrimental effect that alters Bruch's membrane to a greater extent than other structures (Fu et al., 2007; McLaughlin et al., 2007) . . Domain structures of EFEMP1 and modular gene structure for EGF-like domains based on variant 2. DSL, Delta-SerrateLag (DSL) motif is a motif unique to Delta/Serrate/LAG-2 proteins in addition to repeated copies of EGF motif (Lissemore and Starmer, 1999) .
Implicated in
Brain cancer
Note EFEMP1 was found to be highly expressed in malignant gliomas and in glioma cells with activation of Notch signaling (Hu et al., 2012; Hu et al., 2009 ). However, EFEMP1 expression is positively associated with survival of patients with the highest grade of glioma -glioblastoma multiforme (GBM) and consistently, EFEMP1 was shown to suppress highly proliferative GBM cell growth in vivo by attenuation of EGFR-AKT signaling activities and VEGFA-induced angiogenesis (Hu et al., 2011) . Along with activation of Notch pathway, EFEMP1 was shown to enhance migration/invasion and growth in vivo by glioma cells high in Notch signaling and stem-like feature (Hu et al., 2012) . The contradictory roles of EFEMP1 to the growth of different glioma cells suggest EFEMP1 context-dependent function, thus could be an interesting gene to study glioma initiation, progression and tumor heterogeneity.
Breast cancer
Note Hypermethylation of EFEMP1 promoter was found to be the major cause of EFEMP1 expression downregulation in 50-60% sporadic breast cancer (SBC). Tumor suppressive function of EFEMP1 is implicated in SBC by a favorable prognosis effect of EFEMP1 expression to survival, particularly node-positive patients who received adjuvant anthracycline-based chemotherapy, but not in those treated by either cyclophosphamide-methotrexate-5-fluorouracil (CMF) or tamoxifen (Sadr-Nabavi et al., 2009).
Cervical cancer
Note EFEMP1 protein expression was found to be significantly higher in cervical carcinoma with lymph node metastasis and correlates with poor patient survival (En-lin et al., 2010) . Tumor-promoting effect of EFEMP1 in cervical cancer is supported by its function in promoting growth in vivo and in vitro invasion by cervical cancer cell line Hela .
Colorectal cancer
Note Hypermethylation of EFEMP1 promoter was reported in 38,8% colorectal cancer (CRC), which is correlated with downregulation of EFEMP1 expression and cancer progression to advanced pathological stage with lymph node metastasis. Tumor suppressive function of EFEMP1 is implicated in CRC by a favorable prognosis effect of EFEMP1 expression to overall survival and disease-free survival (Tong et al., 2011) .
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Atlas Genet Cytogenet Oncol Haematol. 2013; 17(2) Liver cancer Note Hypermethylation of EFEMP1 promoter was reported in 50% hepatocellular carcinoma (HCC), which is correlated with downregulation of EFEMP1 expression. Tumor suppressive function of EFEMP1 is implicated in liver cancer by unfavorable prognosis from promoter methylation of EFEMP1 (Nomoto et al., 2010) .
Lung cancer
Note Hypermethylation of EFEMP1 promoter was independently reported by two laboratories in 36% and 43% of non-small cell lung carcinoma (NSCLC), while it was rarely found in the matched normal samples (Wang et al., 2010; Yue et al., 2007; Zhang et al., 2011) . It is correlated with downregulation of EFEMP1 expression and cancer progression to advanced pathological stage and lymph node metastasis. Tumor suppressive function of EFEMP1 in lung cancer cell is demonstrated by its suppression effect on anchorage independent growth and in vitro invasion via suppression the expression of matrix metalloproteinase, including MMP2, MMP7, and MMP9 (Kim et al., 2012) .
Nasopharyngeal carcinoma
Note
Hypermethylation of EFEMP1 promoter has been revealed in nasopharyngeal carcinoma (NPC) tumours compared with normal tissues. Downregulation of EFEMP1 expression was found in NPC at advanced lymph node-metastasis stages and a poor 5-year survival rate. Tumor suppressive function of EFEMP1 in NPC is revealed by suppressing migration and invasion of NPC-derived cells and correspondingly decreasing the AKT phosphorylation (Hwang et al., 2010) .
Pancreatic cancer
Note EFEMP1 was reported to bind EGFR and activate MAPK and AKT pathways in pancreatic carcinoma cells and promote in vivo tumor growth with a stimulation of VEGFA production by tumors Seeliger et al., 2009 ).
Prostate cancer
Note Hypermethylation of EFEMP1 promoter was reported in 95,3% of prostate cancer (PCa) but 13,4% of benign prostate hyperplasia (BPH), and EFEMP1 expression was significantly higher in tissue samples from patients with BPH than in those with PCa (Kim et al., 2011) .
Werner syndrome
Note S1-5 mRNA is overexpressed in Werner syndrome and senescent human diploid fibroblasts (LeckaCzernik et al., 1995) .
Adult height
Note
The EFEMP1 locus is one of 20 loci identified in a genome-wide association analysis that influence adult height (Okada et al., 2010) .
